VECTUS BIOSYSTEMS LIMITED — Investor Presentation 2026

VECTUS BIOSYSTEMS

17 June 2026

Meet the CEO Investor Webinar

Vectus Biosystems Limited (ASX:VBS) (Vectus or the Company) is pleased to announce that Dr Tara Speranza will conduct an investor webinar following her recent appointment as Chief Executive Officer and Chief Technology Officer (CEO and CTO) of the Company.

The webinar will provide Vectus' shareholders and interested parties with an update on the Company's strategic direction, corporate priorities and development plans. Dr Speranza will discuss the initiatives being implemented to advance Vectus' antifibrotic pipeline, including the development strategy for its lead asset, VB0004, in idiopathic pulmonary fibrosis (IPF), regulatory and clinical objectives, business development activities and key upcoming milestones.

The webinar will also provide an opportunity to hear directly from Dr Speranza regarding management's vision for the Company, and the execution of Vectus' strategy as it progresses towards its next phase of growth and value creation.

When: 11am AEST, on Tuesday, 23 June 2026

Register at: https://us02web.zoom.us/webinar/register/WN_Cdufwnw-QVSzK2B9Cir73A

Upon registering attendees will receive an email containing information about joining the webinar. A recording will be available at the above link soon after the conclusion of the live session.

Questions can be sent in advance of the webinar to [email protected]

Ronald Shnier
Chairman

Tara Speranza
CEO and CTO
[email protected]

This announcement was authorised by the Board of Directors.

About Vectus Biosystems Limited

Vectus Biosystems Limited (ASX:VBS) is an Australian clinical-stage biotechnology company developing novel therapies for fibrotic diseases, with an initial focus on advancing its lead compound, VB0004, for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, and often fatal, lung disease with significant unmet medical need. VB0004 is a first-in-class antifibrotic candidate that has demonstrated the ability to reverse established fibrosis in preclinical models, and has successfully completed Phase Ia clinical studies, establishing a favourable safety and pharmacokinetic profile.

Beyond IPF, the Company is advancing a broader pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis, leveraging a platform approach to address diseases driven by pathological tissue scarring. The commercial potential of the platform has been externally validated through a licensing agreement with an international biotechnology company for one of Vectus' renal fibrosis assets, showing a pathway for potential future milestone and royalty revenues.

The Company will continue its clinical development with an ambition to create shareholder value through the advancement, partnering and commercialisation of innovative therapies that address significant unmet needs in fibrotic disease.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

Unit 5, Ground Floor, 26-34 Dunning Avenue, Rosebery NSW 2018 Australia

Telephone: +61 2 8344 1300, Facsimile: +61 2 9697 0944

Email: [email protected]

Website: www.vectusbiosystems.com.au